Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden-Reference-Cited by-同舟云学术

Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden

Published:2021-04-13 Issue:2 Volume:114 Page:217-221
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Nozaki Kenji^ORCID,Sugahara Hiroyuki,Ueda Shuji,Ishikawa Jun,Karasuno Takahiro,Iida Masato,Kamae Tsuyoshi,Moriyama Yasuhiro,Kawakami Manabu,Kosugi Satoru,Nakagawa Masashi,Azenishi Yasuhiko,Sakaniwa Ryoto,Kitamura Tetsuhisa,Shibayama Hirohiko

Funder

Eisai

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-021-03151-5.pdf

Reference4 articles.

1. Nozaki K, Sugahara H, Ueda S, Ishikawa J, Fuji S, Masaie H, et al. Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphoma. Leuk Lymphoma. 2020;61(9):2113–21.

2. Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P, et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol. 2012;23(9):2380–5.

3. Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110–7.

4. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.